Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.44 |
| ▸ | MAP2K4 | P45985 | 8/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.41 |
| ▸ | MAPKAPK3 | Q16644 | 4/20 | 0.41 |
| ▸ | MAPK6 | Q16659 | 4/20 | 0.41 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.41 |
| ▸ | MAPKAPK5 | Q8IW41 | 2/20 | 0.41 |
| ▸ | JAK2 | O60674 | 3/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.40 |
| ▸ | CDK2 | P24941 | 3/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.40 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.40 |
| ▸ | CDC7 | O00311 | 2/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.40 |
| ▸ | PIM1 | P11309 | 2/20 | 0.40 |
| ▸ | HIPK2 | Q9H2X6 | 2/20 | 0.40 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.40 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.40 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8365109 | 0.87 | MKNK1 (0.60) | MKNK1MAP2K4MAPK1MAPKAPK3MAPK6 | |
| SCHEMBL8260182 | 0.87 | MKNK1 (0.60) | MKNK1MAP2K4MAPK1MAPKAPK3MAPK6 | |
| SCHEMBL8252132 | 0.85 | MAPK1 (0.42) | MKNK1MAP2K4MAPK1MAPKAPK3MAPK6 | |
| SCHEMBL5382842 | 0.82 | PRKAG1 (0.48) | MKNK1MAP2K4MAPK1MAPKAPK3MAPK6 | |
| SCHEMBL5372735 | 0.80 | MAPKAPK2 (0.48) | MKNK1MAPKAPK2JAK2MAP4K4CDK2 | |
| SCHEMBL8252141 | 0.80 | MAPKAPK2 (0.46) | MKNK1MAP2K4MAPK1MAPKAPK3MAPK6 | |
| SCHEMBL8258328 | 0.80 | MAP2K4 (0.59) | MKNK1MAP2K4PIM1CLK2DYRK1A | |
| SCHEMBL8257794 | 0.79 | CDK2 (0.45) | MKNK1MAP2K4MAPK1MAPKAPK3MAPK6 | |
| SCHEMBL8258334 | 0.79 | AURKA (0.58) | MKNK1MAP2K4MAPK1MAPKAPK2JAK2 | |
| SCHEMBL1774400 | 0.78 | ALPL (0.46) | MKNK1MAPK1MKNK2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7220771-B2 | Methods of using indazole derivatives as JNK inhibitors | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-22 | — | — | US | disclosed |
| US-7220771-B2 | Methods of using indazole derivatives as JNK inhibitors | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-22 | — | — | US | disclosed |
| US-7211594-B2 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-01 | — | — | US | disclosed |
| US-7211594-B2 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-01 | — | — | US | disclosed |
| US-7208513-B2 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-04-24 | — | — | US | disclosed |
| US-7208513-B2 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-04-24 | — | — | US | disclosed |
| US-20050009876-A1 | Indazole compounds, compositions thereof and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2005-01-13 | — | — | US | disclosed |
| US-20050009876-A1 | Indazole compounds, compositions thereof and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2005-01-13 | — | — | US | disclosed |
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | SIGNAL PHARMACEUTICALS, LLC | 2004-07-01 | — | — | US | disclosed |
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | SIGNAL PHARMACEUTICALS, LLC | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | MAPK1, MAP3K1, MAPKAPK2 | MKNK1 66/4885MAP2K4 130/4885MAPK1 1/4885 |
| US-20050009876-A1 | Indazole compounds, compositions thereof and methods of treatment therewith | GPR119, JAK3, IGF1R | MKNK1 65/4885MAP2K4 385/4885MAPK1 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.